Pharma company reports stellar results; revenue surge 40% and profit jumps 67% in 9MFY26

DSIJ Intelligence-1 / 29 Jan 2026 / Categories: Mindshare, Trending

Pharma company reports stellar results; revenue surge 40% and profit jumps 67% in 9MFY26

The stock is up by 9.3 per cent from its 52-week low of Rs 18.53 per share and has given multibagger returns of 155 per cent in 2 years.

Sudarshan Pharma Industries Ltd., incorporated in 2008, is a Mumbai-based company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs) and pharmaceutical items, alongside trading in chemicals and solvents. They offer a diverse portfolio, from bulk chemicals and intermediates to finished formulations, with numerous products registered under their "R" trademark, including popular brands like Love Birds and Metfocal. The company operates both in India and international markets, including exports to countries in Southeast Asia, the Middle East and North Africa.

According to the Quarterly Results, the net sales increased by 16 per cent to Rs 168.01 crore in Q3FY26 compared to Q3FY25. The company reported a net profit of Rs 4.36 crore in Q3FY26, an increase of 51 per cent compared to Q3FY25. For nine-month results, the net sales increased by 40 per cent to Rs 482.14 crore and net profit increased by 67 per cent to Rs 12.58 crore in 9MFY26 compared to 9MFY25. In its annual results, the net sales increased by 9 per cent to Rs 505 crore and net profit increased by 45 per cent to Rs 16 crore in FY25 compared to FY24.

Every portfolio needs a growth engine. DSIJ’s Flash News Investment (FNI) provides weekly stock market insights and recommendations, tailored for both short-term traders and long-term investors. Download PDF Service Note Here

Additionally, the company has expanded its global footprint by incorporating a wholly-owned subsidiary, Sudarshan Pharma Company Poland Limited Liability, in Warsaw. Following board approval in February 2025, the company invested PLN 5,000 for a 100 per cent stake, aiming to leverage this new entity to broaden its customer base within the European market. The subsidiary is set to specialise in the manufacture of chemicals, fertilisers, and plastics, as well as the wholesale of pharmaceutical products, positioning the parent company for significant industrial growth in the international chemical and agrochemical sectors.

The company has a market cap of over Rs 400 crore and has delivered a good profit growth of 70 per cent CAGR over the last 5 years. The stock is up by 9.3 per cent from its 52-week low of Rs 18.53 per share and has given multibagger returns of 155 per cent in 2 years.

Disclaimer: The article is for informational purposes only and not investment advice.